Featured Publications
Intratumour heterogeneity, from hypothesis to the clinic
Shan NL, Kahn A, Pusztai L. Intratumour heterogeneity, from hypothesis to the clinic. British Journal Of Cancer 2022, 128: 459-460. PMID: 36216884, PMCID: PMC9938204, DOI: 10.1038/s41416-022-02008-w.Commentaries, Editorials and Letters
2018
Participation of xCT in melanoma cell proliferation in vitro and tumorigenesis in vivo
Shin S, Jeong B, Wall B, Li J, Shan N, Wen Y, Goydos J, Chen S. Participation of xCT in melanoma cell proliferation in vitro and tumorigenesis in vivo. Oncogenesis 2018, 7: 86. PMID: 30425240, PMCID: PMC6234219, DOI: 10.1038/s41389-018-0098-7.Peer-Reviewed Original ResearchMelanoma cell proliferationCell proliferationXCT expressionPhase II clinical trialDose-dependent decreasePost-treatment specimensTumor biopsy samplesXenograft-bearing animalsMelanoma cell growthHuman melanoma cell linesHuman tumor biopsy samplesCultured human melanomaStable diseaseMelanoma cell linesAggressive tumorsCancer stageClinical trialsTumor biopsiesXenograft studiesRiluzoleBiopsy samplesMost melanomasHuman melanomaTumor progressionWestern immunoblot analysis